Market Place
Sourcing Support
Puma Biotech Initiates ALISCA™-Breast1 Phase II Trial of Alisertib
20 Nov 2024 //
BUSINESSWIRE
Puma`s Alisertib Phase 1/1b Data In Advanced EGFR-Mutant Lung Cancer
03 Jun 2024 //
BUSINESSWIRE
Puma`s Alisertib Shows Findings In Endocrine-Resistant Metastatic Breast Cancer
02 Jun 2024 //
BUSINESSWIRE
Puma Alisertib Asco Abstracts: 2024 Annual Meeting Titles Published
23 May 2024 //
BUSINESSWIRE
Puma Announces FDA Allowance to Proceed Under IND for Alisertib in Breast Cancer
20 Mar 2024 //
BUSINESSWIRE
Puma Bio Announces Initiation of ALISCA-Lung1 Phase II Trial of Alisertib
13 Feb 2024 //
BUSINESSWIRE
Puma Biotechnology Announces Phase II Clinical Trial Design for Alisertib
11 Dec 2023 //
BUSINESSWIRE
Puma Announces Presentation of Findings from a Phase I/II Study of Alisertib
14 Oct 2023 //
BUSINESSWIRE
Puma Biotechnology Receives FDA Orphan Drug Designation for Alisertib
21 Sep 2023 //
BUSINESSWIRE
Puma Announces Presentation of Biomarker Findings from PII Study of Alisertib
04 Jun 2023 //
BUSINESSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.